- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
437
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
437 companies
Zura Bio
Market Cap: US$148.9m
A clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States.
ZURA
US$2.10
7D
2.4%
1Y
-47.1%
Climb Bio
Market Cap: US$148.4m
A clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.
CLYM
US$2.10
7D
-6.3%
1Y
-58.0%
Nkarta
Market Cap: US$146.3m
A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
NKTX
US$2.00
7D
0.5%
1Y
-56.3%
Eledon Pharmaceuticals
Market Cap: US$144.9m
Operates as a clinical stage biotechnology company.
ELDN
US$2.47
7D
-3.1%
1Y
-2.8%
Corbus Pharmaceuticals Holdings
Market Cap: US$141.2m
A biopharmaceutical company, develops products to defeat serious illness.
CRBP
US$12.14
7D
4.5%
1Y
-43.5%
Jushi Holdings
Market Cap: US$139.4m
A vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for the medical and adult-use markets in the United States.
JUSH.F
US$0.61
7D
-11.4%
1Y
14.4%
Cardiff Oncology
Market Cap: US$137.7m
A clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers.
CRDF
US$2.04
7D
-5.6%
1Y
-26.1%
biote
Market Cap: US$136.6m
Operates in practice-building business within the hormone optimization space.
BTMD
US$2.97
7D
-11.9%
1Y
-45.5%
Inovio Pharmaceuticals
Market Cap: US$133.9m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$2.43
7D
5.2%
1Y
-55.9%
Compugen
Market Cap: US$130.9m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$1.38
7D
3.0%
1Y
-21.1%
Anika Therapeutics
Market Cap: US$130.8m
A joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
ANIK
US$9.00
7D
0.7%
1Y
-63.5%
Alpha Cognition
Market Cap: US$129.3m
A biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
ACOG
US$7.72
7D
-10.0%
1Y
-22.8%
Inhibikase Therapeutics
Market Cap: US$128.2m
Operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders.
IKT
US$1.55
7D
0.6%
1Y
34.8%
Oncolytics Biotech
Market Cap: US$125.5m
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
ONCY
US$1.25
7D
-8.1%
1Y
39.3%
Instil Bio
Market Cap: US$118.6m
A clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
TIL
US$16.65
7D
-20.8%
1Y
-75.6%
Sera Prognostics
Market Cap: US$117.6m
A women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
SERA
US$2.95
7D
-7.8%
1Y
-60.2%
Spero Therapeutics
Market Cap: US$110.9m
A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
SPRO
US$1.94
7D
-3.0%
1Y
51.6%
Fortress Biotech
Market Cap: US$109.8m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.75
7D
5.3%
1Y
158.6%
Zentalis Pharmaceuticals
Market Cap: US$109.6m
A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
ZNTL
US$1.49
7D
0%
1Y
-59.6%
MacroGenics
Market Cap: US$108.7m
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
MGNX
US$1.65
7D
-4.6%
1Y
-45.7%
Atossa Therapeutics
Market Cap: US$106.6m
Operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
ATOS
US$0.82
7D
-7.2%
1Y
-41.2%
Vistagen Therapeutics
Market Cap: US$106.5m
A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
VTGN
US$3.37
7D
10.9%
1Y
12.3%
Alto Neuroscience
Market Cap: US$105.1m
Operates as a clinical-stage biopharmaceutical company in the United States.
ANRO
US$3.80
7D
-7.5%
1Y
-68.3%
Entasis Therapeutics Holdings
Market Cap: US$104.8m
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States.
ETTX
US$2.19
7D
0%
1Y
-14.8%
IO Biotech
Market Cap: US$104.1m
A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
IOBT
US$1.58
7D
-2.5%
1Y
47.7%
Atara Biotherapeutics
Market Cap: US$100.2m
Engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.
ATRA
US$13.83
7D
14.6%
1Y
80.5%
Burning Rock Biotech
Market Cap: US$98.1m
Develops and sells cancer therapy selection tests in the People's Republic of China and the United States.
BNR
US$9.11
7D
8.3%
1Y
168.7%
Adagene
Market Cap: US$95.7m
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
ADAG
US$2.02
7D
-2.4%
1Y
-9.8%
Werewolf Therapeutics
Market Cap: US$94.9m
A biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions.
HOWL
US$2.02
7D
39.3%
1Y
-3.8%
aTyr Pharma
Market Cap: US$93.2m
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
ATYR
US$0.89
7D
-14.9%
1Y
-48.7%
Coya Therapeutics
Market Cap: US$93.0m
A clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
COYA
US$5.31
7D
-7.5%
1Y
-15.4%
InflaRx
Market Cap: US$92.1m
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
IFRX
US$1.29
7D
-5.8%
1Y
-16.2%
Assertio Holdings
Market Cap: US$91.8m
A pharmaceutical company, provides various products to patients in the United States.
ASRT
US$0.93
7D
-5.1%
1Y
-24.2%
Nautilus Biotechnology
Market Cap: US$91.0m
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
NAUT
US$0.82
7D
12.8%
1Y
-71.2%
Pliant Therapeutics
Market Cap: US$89.6m
A biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases.
PLRX
US$1.44
7D
-3.4%
1Y
-87.1%
Champions Oncology
Market Cap: US$88.9m
A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
CSBR
US$6.39
7D
-4.6%
1Y
32.8%